CN116392486A - Pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof - Google Patents
Pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof Download PDFInfo
- Publication number
- CN116392486A CN116392486A CN202310614537.6A CN202310614537A CN116392486A CN 116392486 A CN116392486 A CN 116392486A CN 202310614537 A CN202310614537 A CN 202310614537A CN 116392486 A CN116392486 A CN 116392486A
- Authority
- CN
- China
- Prior art keywords
- cerebral apoplexy
- pharmaceutical composition
- preventing
- ischemic cerebral
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 41
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 40
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 39
- 208000006011 Stroke Diseases 0.000 title claims abstract description 39
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 29
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960003266 deferiprone Drugs 0.000 claims abstract description 26
- HUUSXLKCTQDPGL-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea Chemical compound CC(C)(O)C1=COC(S(=O)(=O)NC(=O)NC=2C=3CCCC=3C=C3CCCC3=2)=C1 HUUSXLKCTQDPGL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 229960005235 piperonyl butoxide Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 16
- 206010061216 Infarction Diseases 0.000 abstract description 7
- 230000034994 death Effects 0.000 abstract description 7
- 230000007574 infarction Effects 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 208000028389 Nerve injury Diseases 0.000 abstract description 5
- 230000008764 nerve damage Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000010172 mouse model Methods 0.000 abstract description 2
- 229960003495 thiamine Drugs 0.000 description 9
- 239000011721 thiamine Substances 0.000 description 9
- LFQQNXFKPNZRFT-UHFFFAOYSA-M sodium 1,2,3,5,6,7-hexahydro-s-indacen-4-ylcarbamoyl-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylazanide Chemical compound [Na+].CC(C)(O)c1coc(c1)S(=O)(=O)[N-]C(=O)Nc1c2CCCc2cc2CCCc12 LFQQNXFKPNZRFT-UHFFFAOYSA-M 0.000 description 7
- -1 1, 2,3,5,6, 7-Hexahydro-s-indacen-4-ylcarbamoyl Chemical group 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 239000000306 component Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 3
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940061130 deferiprone 500 mg Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof, relates to the technical field of medicines, and solves the technical problems that no special method is available for the ischemic cerebral apoplexy and clinical prevention and treatment effects are limited in the prior art. The invention relates to a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy, which consists of the following compounds or salts thereof: sulfoxylamine, deferiprone and MCC950; the weight ratio of the sulfoxylamine, the deferiprone and the MCC950 is 10-40:10-40:1-4. The pharmaceutical composition for preventing and treating ischemic cerebral apoplexy can obviously reduce the death rate, infarct area, nerve injury and inflammatory factor level of a mouse model of the ischemic cerebral apoplexy, can provide a new medicine source for treating the ischemic cerebral apoplexy, and has potential significant economic and social benefits.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof.
Background
Ischemic cerebral apoplexy is a sudden onset brain blood circulation disorder refractory disease, has the characteristics of high morbidity, disability rate and mortality rate, and seriously endangers the health of human beings. At present, no specific method is available for clinically treating the serious disease, and the clinical prevention and treatment effects are limited, so that serious challenges are faced. Development of a novel medicine for improving ischemic cerebral apoplexy and reduction of the death rate of cerebral apoplexy are very necessary and urgent.
Disclosure of Invention
The invention discloses a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof, and solves the technical problems that no specific method exists for the ischemic cerebral apoplexy and clinical prevention and treatment effects are limited in the prior art.
In order to solve the problems, the invention adopts the following technical scheme:
the first aspect of the invention provides a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy.
The invention relates to a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy, which consists of the following compounds or salts thereof:
sulfoxylamine, deferiprone and MCC950;
the weight ratio of the sulfoxylamine, the deferiprone and the MCC950 is 10-40:10-40:1-4.
MCC950 is NLRP3 inhibitor with the molecular formula: c (C) 20 H 24 N 2 O 5 S, english name is: n- (1, 2,3,5,6, 7-Hexahydro-s-indacen-4-ylcarbamoyl) -4- (2-hydroxy-2-process) -2-furansulfonamide.
Preferably, the weight ratio of the sulfoxylamine-butyl-thiamine to the deferiprone to the MCC950 is 10-20:10-20:1-2.
Preferably, the pharmaceutical composition for preventing and treating ischemic cerebral apoplexy also comprises pharmaceutically acceptable auxiliary materials or auxiliary components.
Preferably, the pharmaceutical composition for preventing and treating ischemic cerebral apoplexy is a preparation prepared by adding pharmaceutically acceptable auxiliary materials or auxiliary components into active ingredients of sulfoxylamine or salts thereof, deferiprone or salts thereof and MCC950 or salts thereof.
The second aspect of the invention provides application of a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy.
The invention relates to an application of a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy in preparing a medicine for preventing and treating ischemic cerebral apoplexy.
The technical scheme adopted by the invention can achieve the following beneficial effects:
the invention relates to a pharmaceutical composition for preventing and treating ischemic cerebral apoplexy, which consists of the following compounds or salts thereof: the composition comprises the following components of the butafenamide sulfoxide amine, deferiprone and MCC950, wherein the butafenamide sulfoxide amine can obviously reduce copper death of tissues in an ischemic cerebral apoplexy model, deferiprone can obviously reduce iron death of the tissues in the ischemic cerebral apoplexy model, the NLRP3 inhibitor MCC950 can obviously reduce cell apoptosis of the tissues in the ischemic cerebral apoplexy model, and the combination of the butafenamide sulfoxide amine, deferiprone and MCC950 can obviously reduce the death rate, the infarct area, the nerve injury and the inflammatory factor level of a mouse model in the ischemic cerebral apoplexy; the antiplatelet drugs commonly used in the prior art, such as methotrexate, rifampicin, clopidogrel and the like, are easy to cause thrombocytopenia, and most patients have drug resistance to the currently used drugs, compared with the existing antiplatelet drugs, the NLRP3 inhibitor MCC950 used in the invention can reduce the risk of thrombocytopenia and solve the problem of drug resistance of the current users to the existing antiplatelet drugs.
On the other hand, the invention provides the optimal ratio of the components of the pharmaceutical composition, and the invention can better improve ischemic cerebral apoplexy under the ratio. Specifically, the optimal ratio of the butamine sulfoxide amine, the deferiprone and the MCC950 is that the weight ratio of the butamine sulfoxide amine to the deferiprone to the MCC950 is 10-40:10-40:1-4, and particularly preferred ratio is: the weight ratio of the sulfoxylamine, the deferiprone and the MCC950 is 10-20:10-20:1-2.
The application of the pharmaceutical composition can provide a new medicine source for treating cerebral arterial thrombosis, and has potential significant economic and social benefits. The preparation prepared by taking the sulfoxylamine-butyl-thiamine, deferiprone and MCC950 as active ingredients has application prospect as an ischemic cerebral apoplexy prevention and treatment drug, is developed according to a national innovation drug approval method, is hopeful to become an innovation drug for high-efficiency low-toxicity ischemic cerebral apoplexy prevention and treatment, and has wide industrialization prospect.
Namely, the pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and the application thereof solve the technical problems that no specific method exists for preventing and treating ischemic cerebral apoplexy and the clinical prevention and treatment effects are limited in the prior art.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, based on the examples herein, which are within the scope of the invention as defined by the claims, will be within the scope of the invention as defined by the claims.
Example 1
The influence of the pharmaceutical composition of the present invention on the ischemic stroke model will be described in detail in this example.
Grouping and administration: the C57BL/6 mice were randomly divided into 9 groups of 10 each, a sham operation group, a model group, a drug intervention group 1, a drug intervention group 2, a drug intervention group 3, a drug intervention group 4, a drug intervention group 5, a drug intervention group 6, and a drug intervention group 7. And performing drug combination gastric lavage intervention on the drug intervention group 1-the drug intervention group 7, wherein the drug intervention is performed once a day in the morning and evening for 21 days.
Molding and collecting samples: after the last administration for 1h, C57BL/6 mice were anesthetized with sodium pentobarbital and fixed on a stereotactic apparatus in prone position, local sterilization with iodine was performed using an ophthalmic surgical scissors, incisions were made along the right side of the median line of the mouse neck, the right common carotid artery and external carotid artery of the mice were blunt-separated, then the near common carotid artery and external carotid artery of the mice were ligated, the carotid artery was rapidly inserted into a model-dedicated plug by a special hook, the plug was taken out after 1 hour, after one day of modeling was completed, bederson injury and mNSS injury scores were performed, the brains of the mice were taken out after sodium pentobarbital anesthesia, 2,3, 5-triphenyltetrazolium chloride (TTC) staining was performed, brain infarction areas were quantified with Image J software, relevant sample detection factors, platelet data and aggregation were detected, and the values are shown in tables 1 to 6, and the test results are shown as mean value.+ -. SED. n=10 and,P<0.05 was statistically different.
The pharmaceutical intervention group 1-7 comprises the following pharmaceutical components in parts by weight:
drug intervention group 1: 200 mg/kg of sulfoxylamine-b-butyl-thiamine; deferiprone 125 mg/kg; MCC950 sodium salt 10 mg/kg;
drug intervention group 2: 100 mg/kg of sulfoxylamine-b-butyl-thiamine; deferiprone 400/mg/kg; MCC950 sodium salt 40 mg/kg;
drug intervention group 3: 400 mg/kg of sulfoxylamine-b-butyl-thiamine; deferiprone 100 mg/kg; MCC950 sodium salt 10 mg/kg;
drug intervention group 4: 100 mg/kg of sulfoxylamine-b-butyl-thiamine; deferiprone 400/mg/kg; MCC950 sodium salt 10 mg/kg;
drug intervention group 5: 500 mg/kg of sulfoxylamine-b-butyl-thiamine; deferiprone 100 mg/kg; MCC950 sodium salt 50 mg/kg;
drug intervention group 6: 500 mg/kg of sulfoxylamine-b-butyl-thiamine; deferiprone 100 mg/kg; MCC950 sodium salt 10 mg/kg.
Drug intervention group 7: 100 mg/kg of sulfoxylamine-b-butyl-thiamine; deferiprone 500 mg/kg; MCC950 sodium salt 50 mg/kg.
TABLE 1 influence of pharmaceutical combinations on mortality in ischemic stroke modes
Grouping | Mortality (%) |
False operation group | 0 |
Model group | 30 |
Pharmaceutical intervention group 1 | 0 |
Pharmaceutical intervention group 2 | 10 |
Pharmaceutical intervention group 3 | 10 |
Pharmaceutical intervention group 4 | 10 |
Pharmaceutical intervention group 5 | 20 |
Pharmaceutical intervention group 6 | 20 |
Pharmaceutical intervention group 7 | 20 |
Table 1 shows the effect of the pharmaceutical composition on ischemic stroke pattern mortality. From the data in table 1, it can be seen that: the pharmaceutical composition used in the pharmaceutical intervention groups 1-7 can reduce the death rate of ischemic cerebral apoplexy, and especially the pharmaceutical composition used in the pharmaceutical intervention group 1 has the optimal effect. Values are expressed as mean ± SED. n=10, p# <0.05 vs Model.
TABLE 2 influence of pharmaceutical combinations on ischemic stroke model infarct size
Grouping | Infarct size (%) |
False operation group | 0 |
ModelGroup of | 39 ± 5 |
Pharmaceutical intervention group 1 | 7 ± 3 |
Pharmaceutical intervention group 2 | 13 ± 2 |
Pharmaceutical intervention group 3 | 12 ± 4 |
Pharmaceutical intervention group 4 | 11 ± 3 |
Pharmaceutical intervention group 5 | 22 ± 5 |
Pharmaceutical intervention group 6 | 23 ± 4 |
Pharmaceutical intervention group 7 | 20 ± 4 |
Table 2 shows the effect of the pharmaceutical composition on the infarct size in ischemic stroke. From the data in table 2, it can be seen that: the pharmaceutical composition used in the pharmaceutical intervention groups 1-7 can reduce the infarct size of ischemic cerebral apoplexy, and especially the pharmaceutical composition used in the pharmaceutical intervention group 1 has the optimal effect. Values are expressed as mean ± SED. n=10, p# <0.05 vs Model.
TABLE 3 influence of pharmaceutical combinations on ischemic stroke-type nerve injury
Grouping | Neurological score (Bederson score) | Neurological score (mNSS score) |
False operation group | 0 | 18 |
Model group | 2.4 ± 0.3 | 6.1 ± 1.2 |
Pharmaceutical intervention group 1 | 0.8 ± 0.3 | 15.9 ± 0.2 |
Pharmaceutical intervention group 2 | 1.3± 0.2 | 13.2± 0.4 |
Pharmaceutical intervention group 3 | 1.2± 0.2 | 12.1± 0.5 |
Pharmaceutical intervention group 4 | 1.3± 0.3 | 13.5± 0.3 |
Pharmaceutical intervention group 5 | 1.4± 0.2 | 10.2± 0.2 |
Pharmaceutical intervention group 6 | 1.5± 0.3 | 10.5± 0.2 |
Pharmaceutical intervention group 7 | 1.6± 0.3 | 9.5± 0.3 |
Table 3 shows the effect of the pharmaceutical composition on ischemic stroke type nerve injury. From the data in table 3, it can be seen that: the pharmaceutical composition used in the pharmaceutical intervention groups 1-7 can reduce nerve damage of ischemic cerebral apoplexy, and especially the pharmaceutical composition used in the pharmaceutical intervention group 1 has the optimal effect. Values are expressed as mean ± SED. n=10, p# <0.05 vs Model.
TABLE 4 influence of pharmaceutical combinations on serum inflammatory factors of the cerebral arterial thrombosis type
Grouping | Serum IL-1 beta level (ng/mL) |
False operation group | 0.24 ± 0.1 |
Model group | 2.61 ± 0.2 |
Pharmaceutical intervention group 1 | 0.29 ± 0.1 |
Pharmaceutical intervention group 2 | 0.45± 0.2 |
Pharmaceutical intervention group 3 | 0.51± 0.1 |
Pharmaceutical intervention group 4 | 0.43± 0.1 |
Pharmaceutical intervention group 5 | 0.99± 0.1 |
Pharmaceutical intervention group 6 | 1.1± 0.3 |
Pharmaceutical intervention group 7 | 1.2± 0.2 |
Table 4 shows the effect of the pharmaceutical composition on serum inflammatory factors of the ischemic stroke type. From the data in table 4, it can be seen that: the pharmaceutical composition used in the pharmaceutical intervention groups 1-7 can reduce the inflammatory factor level of cerebral tissue of ischemic cerebral apoplexy, and especially the pharmaceutical composition used in the pharmaceutical intervention group 1 has the optimal effect. Values are expressed as mean ± SED. n=10, p# <0.05 vs Model.
TABLE 5 influence of pharmaceutical combinations on platelet count in ischemic stroke modes
Grouping | Platelet count (10) 3 /mL) |
False operation group | 1150 ± 120 |
Model group | 1157 ± 125 |
Pharmaceutical intervention group 1 | 1160 ±125 |
Pharmaceutical intervention group 2 | 1158 ± 120 |
Pharmaceutical intervention group 3 | 1153 ± 119 |
Pharmaceutical intervention group 4 | 1169 ± 124 |
Pharmaceutical intervention group 5 | 1173 ± 145 |
Pharmaceutical intervention group 6 | 1165 ± 135 |
Pharmaceutical intervention group 7 | 1176 ± 145 |
Table 5 shows the effect of the pharmaceutical composition on the number of plasma platelets in the ischemic stroke mode. From the data in table 5, it can be seen that: the pharmaceutical compositions used in the pharmaceutical intervention groups 1-7 have no obvious influence on the number of the platelets, which indicates that the pharmaceutical composition is not easy to cause thrombocytopenia.
TABLE 6 influence of pharmaceutical combinations on platelet aggregation induced by ischemic stroke model thrombin
Grouping | Platelet aggregation (%) |
False operation group | 30 ± 6 |
Model group | 75 ± 12 |
Pharmaceutical intervention group 1 | 32 ± 7 |
Pharmaceutical intervention group 2 | 38 ± 7 |
Pharmaceutical intervention group 3 | 43 ± 5 |
Pharmaceutical intervention group 4 | 45 ±4 |
Pharmaceutical intervention group 5 | 53 ± 7 |
Pharmaceutical intervention group 6 | 55 ± 6 |
Pharmaceutical intervention group 7 | 52 ± 7 |
Table 6 shows the effect of the pharmaceutical composition on the degree of platelet aggregation in the ischemic stroke mode. From the data in table 6, it can be seen that: the pharmaceutical composition used in the pharmaceutical intervention groups 1-7 can reduce the platelet aggregation degree induced by ischemic cerebral apoplexy type thrombin (0.01U/mL, 5 min), and especially the pharmaceutical composition used in the pharmaceutical intervention group 1 has the optimal effect. Values are expressed as mean ± SED. n=10, p# <0.05 vs Model.
From the data, the combined medicines, namely the sulfoxylamine, the deferiprone and the MCC950, can obviously reduce the death rate, the infarct area, the neurological damage and the inflammatory factor secretion of an ischemic cerebral apoplexy model, reduce the high reactivity of platelets, do not influence the number of platelets, reduce the platelet aggregation degree induced by thrombin and have excellent effect of preventing and treating the ischemic cerebral apoplexy; the above data also demonstrate that the optimum ratios of sulfoxylamine, deferiprone and MCC950 are: the weight ratio is 10-40:10-40:1-4, and particularly preferred ratios are: the weight ratio of the sulfoxylamine, the deferiprone and the MCC950 is 10-20:10-20:1-2.
The foregoing is merely illustrative of the present invention, and the present invention is not limited thereto, and any person skilled in the art will readily recognize that variations or substitutions are within the scope of the present invention.
Claims (5)
1. A pharmaceutical composition for preventing and treating ischemic cerebral apoplexy, which is characterized by comprising the following compounds or salts thereof:
sulfoxylamine, deferiprone and MCC950;
the weight ratio of the sulfoxylamine, the deferiprone and the MCC950 is 10-40:10-40:1-4.
2. The pharmaceutical composition for preventing and treating ischemic stroke according to claim 1, wherein the weight ratio of the sulfoxylamine-busulfan to the deferiprone to the MCC950 is 10-20:10-20:1-2.
3. The pharmaceutical composition for preventing and treating ischemic stroke according to claim 1 or 2, further comprising pharmaceutically acceptable auxiliary materials or auxiliary components.
4. The pharmaceutical composition for preventing and treating ischemic stroke according to claim 3, wherein the preparation is prepared by adding pharmaceutically acceptable auxiliary materials or auxiliary components into active ingredients such as sulfoxylamine butoxide or salts thereof, deferiprone or salts thereof, MCC950 or salts thereof.
5. Use of the pharmaceutical composition for preventing and treating ischemic stroke according to any one of claims 1 to 4 in the preparation of a medicament for preventing and treating ischemic stroke.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310614537.6A CN116392486A (en) | 2023-05-29 | 2023-05-29 | Pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310614537.6A CN116392486A (en) | 2023-05-29 | 2023-05-29 | Pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116392486A true CN116392486A (en) | 2023-07-07 |
Family
ID=87010798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310614537.6A Pending CN116392486A (en) | 2023-05-29 | 2023-05-29 | Pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116392486A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1939895A (en) * | 2000-04-19 | 2007-04-04 | 纽若泰克有限公司 | Compound, composition and method for preventing from neurodegeneration in injury of central nervous system |
US20170172958A1 (en) * | 2014-03-06 | 2017-06-22 | Helga Refsum | Compounds for Use in Controlling Body Fat |
CN113244241A (en) * | 2021-04-04 | 2021-08-13 | 四川大学华西医院 | Pharmaceutical composition for preventing and treating hemorrhagic stroke and application thereof |
-
2023
- 2023-05-29 CN CN202310614537.6A patent/CN116392486A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1939895A (en) * | 2000-04-19 | 2007-04-04 | 纽若泰克有限公司 | Compound, composition and method for preventing from neurodegeneration in injury of central nervous system |
US20170172958A1 (en) * | 2014-03-06 | 2017-06-22 | Helga Refsum | Compounds for Use in Controlling Body Fat |
CN113244241A (en) * | 2021-04-04 | 2021-08-13 | 四川大学华西医院 | Pharmaceutical composition for preventing and treating hemorrhagic stroke and application thereof |
Non-Patent Citations (2)
Title |
---|
SAIFUDEEN ISMAEL等: "Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke", 《SCIENTIFIC REPORTS》, vol. 08 * |
饶政清等: "脑泰方调控细胞铁转运抑制铁死亡保护脑卒中缺血损伤的机制研究", 《中草药》, vol. 52, no. 21, pages 1 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022123073A (en) | Method of treating or reducing efp | |
DE69828881T2 (en) | COMPOSITION TO TREAT DISORDERS OF HUMAN HEALTH IN HEALTHY INDIVIDUALS | |
CN113244241B (en) | Pharmaceutical composition for preventing and treating hemorrhagic stroke and application thereof | |
TW201313228A (en) | New administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide | |
RU2005129333A (en) | 4 - [(2,4-Dichloro-5-methoxyphenyl) amino] -6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic damage | |
KR20010006485A (en) | Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells | |
US11963991B2 (en) | Treatment of warts | |
CN116392486A (en) | Pharmaceutical composition for preventing and treating ischemic cerebral apoplexy and application thereof | |
KR102076137B1 (en) | Decreased contractility accompanying concomitant detrusor muscle overactivity | |
CA2454544A1 (en) | Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient | |
KR20210031466A (en) | Enhancement of antibacterial activity of depsipeptide antibiotics using synergistic boric acid | |
JP2005509663A (en) | Methods for cancer treatment | |
CN115475165B (en) | Application of indacaterol maleate in hemorrhagic brain injury related diseases | |
CN115607545B (en) | Application of edaravone in treatment of autism spectrum disorder | |
WO2022183493A1 (en) | Application of polyphenol compound | |
EP4248970A1 (en) | Opthalmic compositions comprising cetirizine and tocofersolan | |
TW202216145A (en) | Ameliorating agent or prophylactic agent for muscle weakness symptom in disease or syndrome associated with metabolic disorder | |
CN116407557A (en) | Pharmaceutical composition for preventing and treating cerebral arterial thrombosis and application thereof | |
JP2017088559A (en) | Filaggrin production enhancer | |
CN105560236B (en) | A kind of pharmaceutical composition and its preparation method and application containing ginkolide B and non-peptide batroxobin inhibitor | |
JP2024064835A (en) | Rabies post-exposure treatment agent | |
JP2015229671A (en) | Retinal pigment epithelial cell protectant | |
WO2022213230A1 (en) | Drug combination and use thereof in preparation of drug for preventing and treating cerebral ischemic stroke | |
CN117897151A (en) | Methods for treating parkinson's disease | |
CN115715191A (en) | Therapeutic agent for urination symptom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230707 |
|
RJ01 | Rejection of invention patent application after publication |